Thursday, March 28, 2019 4:13:08 PM
Coach, it's great to read your posts. Overall this board is a great place to follow the science and development of the company. And if we get the kind of results that we hope for and that seem likely based on everything we know then this has also been the place where all the eyes of AD community should have been focused on.
Recent SNPX News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2024 02:21:09 PM
- Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength • PR Newswire (US) • 12/20/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2024 10:06:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 10:00:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/07/2024 01:54:38 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/05/2024 11:01:09 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/28/2024 08:00:16 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/10/2024 09:11:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 08:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 08:54:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 01:00:53 PM
- Synaptogenix Announces $5.0 Million Financing • PR Newswire (US) • 09/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 09:00:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:30:55 PM
- Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury • PR Newswire (US) • 07/18/2024 01:00:00 PM
- Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics • PR Newswire (US) • 04/09/2024 01:15:00 PM
- Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 04/03/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:16:19 PM
North Bay Resources Announces Operation of New Gravity Circuit at Bishop Gold Mill, California • NBRI • Jan 10, 2025 8:29 AM
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology • BLO • Jan 9, 2025 8:49 AM
UAV Corp. (UMAV) Further Reduces Authorized Shares to 500 Million • UMAV • Jan 8, 2025 2:27 PM
Fifty 1 Labs, Inc. Launches Dedicated Website for Shareholders and Investors, Company now current with OTC Markets • CAFI • Jan 7, 2025 9:00 AM
EzFill Holdings, Inc. Successfully Closes Acquisition of Shell Fleet, Accelerating Nationwide Mobile Fueling Expansion • EZFL • Jan 7, 2025 8:35 AM
CGRA Signs Binding Term Sheet to Merge With American Infrastructure Corporation, a Subsidiary of Nasdaq-listed American Resources Corporation (Nasdaq: AREC) • CGRA • Jan 6, 2025 10:31 AM